(Bayer) Feb 5, 2019 - First presentation of data from the pivotal Phase III ARAMIS trial with the investigational compound darolutamide in patients with non-metastatic castration-resistant prostate cancer.
Read ArticleTomasz M. Beer, MD, FACP (Posted: February 05, 2019)
Daralutamide would be the third agent with demonstrated efficacy in non-metastatic castration resistant prostate cancer if the ARAMIS trial yields positive results. Both efficacy and safety data will be of interest and clinicians evaluate a growing stable of options in this disease state where enzalutamide and apalutamide have been approved.
Professor of Medicine, Division of Hematology/Medical O...
Professor and Director, Division of Hematology Oncology...